This Week in JAMA

Premium

In JAMA this week, researchers in the US and Europe say they've developed a genomic predictor of response and survival for taxane-anthracycline chemotherapy in invasive breast cancer. In a multicenter study conducted from June 2000 to March 2010, the researchers measured distant relapse-free survival and absolute risk reduction in patients with newly diagnosed ERBB2–negative breast cancer treated with chemotherapy containing sequential taxane and anthracycline–based regimens.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.